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Alterations in 3-Adrenergic
ardiac Innervation and
itric Oxide Signaling in
eart Failure*
Shathiyah Kulandavelu, PHD, Joshua M. Hare, MD
Miami, Florida
Sympathetic activation of cardiac beta-adrenergic signaling
pathways modulates inotropic, chronotropic, and lusitropic
responses, providing fundamental control over cardiac re-
serve responses (1). Classically these effects are mediated
through the 7-transmembrane spanning, G-protein coupled
receptors, 1- and 2-adrenoceptors (ARs), which couple
to adenylyl cyclase production of cyclic adenosine mono-
phosphate (cAMP) via Gs (Fig. 1). Over the past 2 decades,
it has become appreciated that the adrenergic nervous
system within the heart also contains a negative regulator of
inotropy and cardiac reserve, acting through a third -AR
(3) (2). Activation of the 3-AR exerts its effects through
i coupling to cyclic guanine monophosphate-nitric oxide
(cGMP-NO) (3). Thus, adrenergic activation of the heart
comprises an internal breaking mechanism that offsets
maximal activation of cardiac cAMP responses (4).
See page 1979
3-ARs have classically been considered mediators of
metabolic effects (i.e., promoting lipolysis and energy ex-
penditures) in adipose tissue (5), but the discovery of their
expression in human ventricular myocardium (2) has added
a crucial insight into the complexities of adrenergic cardiac
regulation in heart failure. As 1 and 2 receptors are
lassically appreciated to be down-regulated in heart failure
6), it has become important to examine the fate of the 3
eceptor and its downstream signaling under similar states
f stress. 3-ARs are up-regulated in heart failure (6) but
hether this up-regulation is a protective response to
drenergic overactivity (a hallmark of heart failure) or a
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relationships relevant to the contents to this paper to disclose.ontributor to heart failure remains to be resolved. Further-
ore, it is well established that the negative inotropic effects
f 3-AR result from downstream production of nitric
oxide (NO) by nitric oxide synthase (NOS) signaling (3,4),
and could thus have favorable effects. In this context, NOSs
are also fundamentally altered in both abundance and spatial
localization in the failing heart (1,7), and the impact of this
shift on 3 cardiac innervation in heart failure has hereto-
ore remained incompletely elucidated.
The contribution of Niu et al. (8) in this issue of the
ournal addresses these important issues. Using a mouse
odel of pressure overload induced by transverse aortic
onstriction (TAC), they show that 3-AR stimulation
ith a 3-agonist (BRL 37344) reduced cardiac remodeling
nd improved cardiac function after 3 weeks of treatment.
hey propose that this reduction occurs via restoration in
itroso-redox balance (9), arising from a neuronal NOS
nNOS)–dependent increase in NO generation accompa-
ied by reactive oxygen species reduction. Using specific
NOS inhibitors and nNOS knockout (KO) mice, they
urther demonstrate that nNOS as opposed to endothelial
OS (eNOS) was the primary downstream isoform main-
aining NO and reactive oxygen species balance in the
ailing heart.
These findings fit well within the existing knowledge base
egarding nNOS translocation in the failing heart, in which
NOS increases in abundance and translocates from the
arcoplasmic reticulum (SR) to the sarcolemma under con-
itions of cardiac stress (10–12). Although the current
nvestigation did not examine nNOS subcellular localiza-
ion, this finding is highly consistent within animal models
f myocardial injury and in humans with cardiomyopathy
10–12). It has previously been well established that under
hysiological conditions, eNOS is the primary NOS iso-
orm participating in 3-induced negative inotropy (3,4).
Yet, in this current study, Niu et al. (8) show that eNOS
may actually be deactivated by 3-AR stimulation in that
er1177 phosphorylation was decreased, whereas Ser114
hosphorylation was increased following BRL treatment.
urthermore, eNOS uncoupling induced by TAC was not
eversed by BRL treatment (8).
In an important additional twist on the interaction
etween 3-AR and nNOS, Niu and colleagues show that
3-AR stimulation further up-regulated nNOS protein,
consistent with a feed-forward mechanism. Moreover, BRL
stimulation of 3-AR worsened cardiac hypertrophy and
eft ventricular (LV) dysfunction induced by TAC in nNOS
O mice (8). This finding shows very clearly that nNOS
p-regulation (likely accompanied by translocation to the
arcolemma) is an adaptive mechanism in the stressed
eart, and is consistent with studies showing that nNOS
O mice developed more severe LV remodeling and
mpaired -adrenergic reserve following myocardial infarc-
tion (MI) compared with control mice (13,14).
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May 29, 2012:1988–90 3-Adrenergic and nNOS in Heart FailureThe mechanism by which the nNOS pathway is involved
in regulating cardiac contractility was not examined in the
current study. As previously mentioned, in normal hearts
(12,15), nNOS is localized to cardiac SR, where it co-
localizes with RyR2 and xanthine oxidoreductase and me-
diates SR Ca2 release (16). Furthermore, our lab has
hown that RyR2 receptors in nNOS KO mice are hyponi-
rosylated, which, in turn, leads to increased diastolic Ca2 leak
nd reduced intra-SR Ca2 content (17). This leakage, in turn,
decreases contractility indicating that in normal hearts, nNOS
facilitates myocardial contractile reserve (7,15,17). Following
MI and in failing myocardium due to dilated cardiomyopathy,
nNOS translocates to the sarcolemma where it binds to
caveolin-3 and PMCA4b (10–12). Translocation of nNOS
from SR to sarcolemma may have dual effects on myocardial
contractility. Increased NO production in caveolae may aug-
ment feedback inhibition of L-type Ca2 channels, whereas
ecreased local NO production at the SR may disrupt normal
-nitrosylation-mediated regulation of SR Ca2-ATPase
(SERCA2A) and RyR2 (18). Furthermore, loss of nNOS-
derived NO from SR may remove the inhibition of
xanthine oxidoreductase, leading to substantial increases
in O2
– production (16), which is up-regulated in failing
earts (19). The resulting nitroso-redox imbalance may
β3
traeh gniliaf-noN A
Gi
SERCA2a
PLB
eNOS
nNOS
XOR
C3
−
RyR
L-TCC
Contractility
−
cAMP
+
β1/ β2
AC
Gs
Figure 1 -AR and NOS Signaling in Healthy and Failing Hearts
(A) In the healthy heart, 1- and 2-adrenoceptors (ARs) mediate a positive inotro
vailing, negative inotropic effect via the Gi-nitric oxide (NO) pathway. Endothelial N
whereas neuronal NO synthase (nNOS) bound to the ryanodine receptor (RyR) and
failure, 1- and 2-ARs are down-regulated or desensitized, and eNOS levels are d
translocates from SR to sarcolemma. This translocation results in nitroso-redox im
shown by Niu et al. (8), nNOS at the sarcolemma is adaptative as transverse aort
cyclase; L-TCC  L-type Ca2 channel; PLB  phospholamban; SERCA2a  sarconhance the risk of unregulated and irreversible RyR2ctivation by O2
–, diastolic Ca2 leak, and depletion of
R Ca2 stores contributing to depressed cardiac con-
ractility (19).
What are the clinical relevance and future perspectives of
he Niu et al. (8) findings? Their findings suggest that
3-ARs, due to their protective and negative inotropic
effects on the myocardium, represent an attractive candidate
target for a novel pharmacological strategy in heart failure.
Previous studies using 3-AR agonists in the treatment of
besity and type 2 diabetes resulted in unfavorable outcomes
n animal and human studies due to lack of potency or
eleterious side effects such as tachycardia and muscle
remor arising from lack of 3-AR selectivity (5). However,
the use of these agonists in heart failure may be more
promising. First, 3-ARs are expressed at levels that can
mediate physiological responses in healthy myocardium (2).
Second, unlike 1-AR, 3-AR is elevated in the myocar-
ium in patients with heart failure from ischemic or dilated
ardiomyopathies (6). Third, 3-AR are more resistant
than 1 and 2) to homologous desensitization (20).
inally, co-treatment with -blockers further increases the
xpression of 3-AR (21). Recent studies using nebivolol,
which has combined properties of a 1-AR antagonist and
3-AR agonist, resulted in concentration-dependent nega-
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ect via the Gs-cAMP pathway, whereas stimulation of the 3-AR exerts a counter-
hase (eNOS) bound to caveolin-3 (C3) is normally found at the sarcolemma,
ine oxidoreductase (XOR) is found in sarcoplasmic reticulum (SR). (B) In heart
gulated, whereas 3-ARs and nNOS levels are up-regulated. Furthermore, nNOS
ce contributing to depressed contractility and impaired calcium handling. As
triction in nNOS knockout mice showed detrimental effects. AC  adenylyl
ic reticulum Ca2 ATPase.pic eff
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xanth
own-re
balan
ic cons
plasmtive inotropic effects through activation of the NOS path-
i
o
t
1
1
1
1
1
2
2
2
2
1990 Kulandavelu and Hare JACC Vol. 59, No. 22, 2012
3-Adrenergic and nNOS in Heart Failure May 29, 2012:1988–90way in nonfailing transplanted human hearts (22), and
improved LV systolic function in mice subjected to MI (23).
While these early observations are exciting and suggest that
3-AR pathway has the potential to become an important
therapeutic target in the treatment of heart failure, more
longitudinal studies in animal models and patients are
needed to examine the effect of long-term stimulation of
cardiac 3-ARs.
In summary, we have now unraveled another layer in
understanding the role of the 3-AR-NO pathway in heart
failure. As shown by Niu and colleagues, the increased
abundance of 3-AR interfaces with another important
ntracellular adaptation in the failing heart, the translocation
f nNOS from SR to sarcolemma. Together these adapta-
ions lead to enhanced 3-NOS signaling, which favorably
offsets the remodeling process. Disrupting the nNOS
downstream signaling is clearly deleterious in TAC, remi-
niscent of previous work in MI (13,14). Together, this
entire body of work supports translational efforts to modu-
late 3-AR-nNOS signaling in the stressed heart due to a
variety of insults, including pressure overload, ischemic
injury, and cardiomyopathy.
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